Background: Diabetic foot ulcers (DFUs) affect 9.1 to 26.1 million individuals globally each year, with 15-25% of those with diabetes mellitus (DM) experiencing them during their lives. DFUs are a major cause of amputations, accounting for 85% of such cases in diabetic patients. Curcumin, a compound from Curcuma longa, shows potential in wound healing through mechanisms such as inhibiting the NLRP3 inflammasome pathway, promoting autophagy, and regulating microRNA expression. This study evaluated the efficacy and safety of C3-DiagardTM Cream in treating DFUs. Methods: This open-label, prospective clinical study assessed the efficacy and safety of C3-DiagardTM cream, containing 0.05mg of Harida (Curcuma longa) extract, in treating and preventing DFUs. The cream was applied twice daily for 12 weeks. Key outcomes were assessed through wound size reduction, pain (VAS score), and any adverse reactions during the treatment. Results: Fifty DM patients (36 males, 14 females; mean age 57.58±12.67 years) were enrolled. Among the patients, 75% (38 individuals) showed a wound healing response between 70% and 99%. The average wound size decreased significantly from 6.63 cm2 at baseline to 1.83 cm2 after 12 weeks, with a mean reduction of 4.8 cm2 (p < 0.05). Pain levels, measured by VAS score, significantly dropped from an average of 8 to 3 (p < 0.05). No adverse reactions were reported, highlighting the cream’s safety. Conclusion: C3-DiagardTM cream is effective in reducing the size of diabetic foot ulcers and alleviating pain, with a favourable safety profile. This study supports the clinical use of C3-DiagardTM as a well-tolerated treatment option for patients with DFUs.
| Published in | International Journal of Diabetes and Endocrinology (Volume 9, Issue 3) |
| DOI | 10.11648/j.ijde.20240903.11 |
| Page(s) | 56-60 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Diabetic Foot Ulcer, Curcumin, Wound Healing, Curcuma Longa
| [1] | Sun X, Li R, Yang X, Yuan L. Efficacy and safety of topical oxygen therapy for diabetic foot ulcers: An updated systematic review and meta-analysis. Int Wound J [Internet]. 2022 May 5 [cited 2023 Dec 4]; 19(8): 2200–9. Available from: |
| [2] | Oliver TI, Mutluoglu M. Diabetic Foot Ulcer. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Dec 1]. Available from: |
| [3] | Alexiadou K, Doupis J. Management of Diabetic Foot Ulcers. Diabetes Ther [Internet]. 2012 Dec [cited 2023 Dec 1]; 3(1): 4. Available from: |
| [4] | Mokhtari M, Razzaghi R, Momen-Heravi M. The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial. Phytotherapy Research [Internet]. 2021 Apr [cited 2023 Dec 4]; 35(4): 2099–107. Available from: |
| [5] |
Jayaprasad K, Ramu J, Iyer S, C R K, Pattatheyil A. Open Labelled Pilot Study of Topically Applied Curcumin Versus Standard Treatment on Chronic Wound Healing. IJCMR [Internet]. 2018 Oct [cited 2023 Dec 4]; 5(10). Available from:
https://www.ijcmr.com/uploads/7/7/4/6/77464738/ijcmr_2199.pdf |
| [6] | Cao M, Duan Z, Wang X, Gong P, Zhang L, Ruan B. Curcumin Promotes Diabetic Foot Ulcer Wound Healing by Inhibiting miR-152-3p and Activating the FBN1/TGF-β Pathway. Mol Biotechnol [Internet]. 2024 Jan 11 [cited 2024 Jan 12]; Available from: |
| [7] | Hicks CW, Selvin E. Epidemiology of Peripheral Neuropathy and Lower Extremity Disease in Diabetes. Curr Diab Rep [Internet]. 2019 Aug 27 [cited 2024 Jan 18]; 19(10): 86. Available from: |
| [8] | Chatterjee N, Ekka NM, Mahajan M, Kumar B, Kumar N, Zia A, et al. Effectiveness of Topical Sucralfate in the Management of Diabetic Foot Ulcers: An Open-Labeled Randomized Study. Cureus [Internet]. 2023 Apr 14 [cited 2024 Jan 11]; 15(4). Available from: |
| [9] | Jiang P, Li Q, Luo Y, Luo F, Che Q, Lu Z, et al. Current status and progress in research on dressing management for diabetic foot ulcer. Front Endocrinol (Lausanne) [Internet]. 2023 Aug 17 [cited 2024 Jan 19]; 14: 1221705. Available from: |
| [10] | Agharazi M, Gazerani S, Huntington MK. Topical Turmeric Ointment in the Treatment of Diabetic Foot Ulcers: A Randomized, Placebo-Controlled Study. Int J Low Extrem Wounds. 2022 Dec 13; 15347346221143222. |
| [11] | Kumari A, Raina N, Wahi A, Goh KW, Sharma P, Nagpal R, et al. Wound-Healing Effects of Curcumin and Its Nanoformulations: A Comprehensive Review. Pharmaceutics [Internet]. 2022 Oct 25 [cited 2024 Jan 18]; 14(11): 2288. Available from: |
APA Style
Ruke, M., Iffat, Maurya, A., Bhise, A., Jose, J. A., et al. (2024). Effectiveness and Tolerability of Topical Curcumin for Management of Diabetic Foot Ulcer: A Pilot Clinical Study. International Journal of Diabetes and Endocrinology, 9(3), 56-60. https://doi.org/10.11648/j.ijde.20240903.11
ACS Style
Ruke, M.; Iffat; Maurya, A.; Bhise, A.; Jose, J. A., et al. Effectiveness and Tolerability of Topical Curcumin for Management of Diabetic Foot Ulcer: A Pilot Clinical Study. Int. J. Diabetes Endocrinol. 2024, 9(3), 56-60. doi: 10.11648/j.ijde.20240903.11
AMA Style
Ruke M, Iffat, Maurya A, Bhise A, Jose JA, et al. Effectiveness and Tolerability of Topical Curcumin for Management of Diabetic Foot Ulcer: A Pilot Clinical Study. Int J Diabetes Endocrinol. 2024;9(3):56-60. doi: 10.11648/j.ijde.20240903.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.ijde.20240903.11,
author = {Milind Ruke and Iffat and Arun Maurya and Avinash Bhise and Jyolsna Agnes Jose and Kesavalu Purushothaman},
title = {Effectiveness and Tolerability of Topical Curcumin for Management of Diabetic Foot Ulcer: A Pilot Clinical Study
},
journal = {International Journal of Diabetes and Endocrinology},
volume = {9},
number = {3},
pages = {56-60},
doi = {10.11648/j.ijde.20240903.11},
url = {https://doi.org/10.11648/j.ijde.20240903.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijde.20240903.11},
abstract = {Background: Diabetic foot ulcers (DFUs) affect 9.1 to 26.1 million individuals globally each year, with 15-25% of those with diabetes mellitus (DM) experiencing them during their lives. DFUs are a major cause of amputations, accounting for 85% of such cases in diabetic patients. Curcumin, a compound from Curcuma longa, shows potential in wound healing through mechanisms such as inhibiting the NLRP3 inflammasome pathway, promoting autophagy, and regulating microRNA expression. This study evaluated the efficacy and safety of C3-DiagardTM Cream in treating DFUs. Methods: This open-label, prospective clinical study assessed the efficacy and safety of C3-DiagardTM cream, containing 0.05mg of Harida (Curcuma longa) extract, in treating and preventing DFUs. The cream was applied twice daily for 12 weeks. Key outcomes were assessed through wound size reduction, pain (VAS score), and any adverse reactions during the treatment. Results: Fifty DM patients (36 males, 14 females; mean age 57.58±12.67 years) were enrolled. Among the patients, 75% (38 individuals) showed a wound healing response between 70% and 99%. The average wound size decreased significantly from 6.63 cm2 at baseline to 1.83 cm2 after 12 weeks, with a mean reduction of 4.8 cm2 (p < 0.05). Pain levels, measured by VAS score, significantly dropped from an average of 8 to 3 (p < 0.05). No adverse reactions were reported, highlighting the cream’s safety. Conclusion: C3-DiagardTM cream is effective in reducing the size of diabetic foot ulcers and alleviating pain, with a favourable safety profile. This study supports the clinical use of C3-DiagardTM as a well-tolerated treatment option for patients with DFUs.
},
year = {2024}
}
TY - JOUR T1 - Effectiveness and Tolerability of Topical Curcumin for Management of Diabetic Foot Ulcer: A Pilot Clinical Study AU - Milind Ruke AU - Iffat AU - Arun Maurya AU - Avinash Bhise AU - Jyolsna Agnes Jose AU - Kesavalu Purushothaman Y1 - 2024/09/06 PY - 2024 N1 - https://doi.org/10.11648/j.ijde.20240903.11 DO - 10.11648/j.ijde.20240903.11 T2 - International Journal of Diabetes and Endocrinology JF - International Journal of Diabetes and Endocrinology JO - International Journal of Diabetes and Endocrinology SP - 56 EP - 60 PB - Science Publishing Group SN - 2640-1371 UR - https://doi.org/10.11648/j.ijde.20240903.11 AB - Background: Diabetic foot ulcers (DFUs) affect 9.1 to 26.1 million individuals globally each year, with 15-25% of those with diabetes mellitus (DM) experiencing them during their lives. DFUs are a major cause of amputations, accounting for 85% of such cases in diabetic patients. Curcumin, a compound from Curcuma longa, shows potential in wound healing through mechanisms such as inhibiting the NLRP3 inflammasome pathway, promoting autophagy, and regulating microRNA expression. This study evaluated the efficacy and safety of C3-DiagardTM Cream in treating DFUs. Methods: This open-label, prospective clinical study assessed the efficacy and safety of C3-DiagardTM cream, containing 0.05mg of Harida (Curcuma longa) extract, in treating and preventing DFUs. The cream was applied twice daily for 12 weeks. Key outcomes were assessed through wound size reduction, pain (VAS score), and any adverse reactions during the treatment. Results: Fifty DM patients (36 males, 14 females; mean age 57.58±12.67 years) were enrolled. Among the patients, 75% (38 individuals) showed a wound healing response between 70% and 99%. The average wound size decreased significantly from 6.63 cm2 at baseline to 1.83 cm2 after 12 weeks, with a mean reduction of 4.8 cm2 (p < 0.05). Pain levels, measured by VAS score, significantly dropped from an average of 8 to 3 (p < 0.05). No adverse reactions were reported, highlighting the cream’s safety. Conclusion: C3-DiagardTM cream is effective in reducing the size of diabetic foot ulcers and alleviating pain, with a favourable safety profile. This study supports the clinical use of C3-DiagardTM as a well-tolerated treatment option for patients with DFUs. VL - 9 IS - 3 ER -
Department of Podiatry, Advance Diabetic Foot and Wound Clinic, Mumbai, India
Department of Podiatry, Advance Diabetic Foot and Wound Clinic, Mumbai, India
Department of Podiatry, Advance Diabetic Foot and Wound Clinic, Mumbai, India
Department of Podiatry, Advance Diabetic Foot and Wound Clinic, Mumbai, India
Department of Innovation, Stabicon Life Sciences Pvt. Ltd, Bangalore, India
Department of Innovation, Stabicon Life Sciences Pvt. Ltd, Bangalore, India
Information